Stephen Feider, an officer of Beta Bionics, Inc., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 8,874 shares of common stock through Merrill Lynch, with an approximate sale date of November 11, 2026.

Key Highlights

  • Proposed sale: Stephen Feider, listed as an officer, intends to sell 8,874 shares of Beta Bionics, Inc. common stock.
  • Aggregate market value: The proposed shares carry an aggregate market value of $152,680.72, according to the filing.
  • Shares outstanding: The filing reports 54,367,067 shares of common stock outstanding.
  • Acquisition source: The 8,874 shares were acquired on November 11, 2026, through stock options from the issuer, with payment made in cash on the same date.
  • 10b5-1 plan: The notice indicates a Rule 10b5-1 plan adoption date of July 31, 2026.
  • Prior sales in past 3 months: Feider also sold 744 shares on November 9, 2026, for gross proceeds of $12,649; 382 shares on November 5, 2026, for $6,508; and 6,675 shares on September 2, 2026, for $129,595.13.
  • Exchange: Beta Bionics, Inc. common stock trades on NASDAQ.

Stephen Feider's Proposed Rule 144 Sale at Beta Bionics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 12, 2026, Stephen Feider, an officer of Beta Bionics, Inc. (NASDAQ:BBNX), is proposing to sell 8,874 shares of the company's common stock. The filing identifies Merrill Lynch, located at 5951 La Sendita, Bldg A., Rancho Santa Fe, California, as the broker through which the proposed sale is to be executed, with an approximate sale date of November 11, 2026.

The filing discloses that the 8,874 shares subject to the proposed sale were acquired on November 11, 2026, via stock options from the issuer, with full cash payment made on that same date. The aggregate market value of the proposed shares is listed as $152,680.72. Beta Bionics, Inc. is headquartered at 11 Hughes, Irvine, California 92618, and the SEC file number associated with the company is 001-42491.

The filing also details Feider's sales of Beta Bionics common stock during the prior three months. These include a sale of 744 shares on November 9, 2026, with gross proceeds of $12,649; a sale of 382 shares on November 5, 2026, with gross proceeds of $6,508; and a sale of 6,675 shares on September 2, 2026, with gross proceeds of $129,595.13. The notice indicates reliance on a Rule 10b5-1 plan adopted on July 31, 2026.

What Was Disclosed

Beta Bionics officer Stephen Feider filed a Form 144 notice proposing the sale of 8,874 common shares with an aggregate market value of $152,680.72, acquired through stock options on November 11, 2026, with the sale to be executed through Merrill Lynch under a Rule 10b5-1 plan adopted July 31, 2026.